|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
47,320,000 |
Market
Cap: |
5.69(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$80.05 - $137.75 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 8.1 |
Insider 6 Months : 8.1 |
Insider 3/6 Months : 16.5 |
|
Guru Rank Number : 1068 |
Guru Rank Value : 0 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Axsome Therapeutics is a biopharmaceutical company developing therapies for the management of central nervous system (CNS) conditions that have limited treatment options. Co.'s primary CNS portfolio includes: AXS-05, which is an oral, investigational N-methyl-D-aspartate receptor antagonist with multimodal activity under development for the treatment of CNS disorders; AXS-07, which is an oral, multi-mechanistic, investigational medicine under development for the acute treatment of migraine; AXS-12, which is an oral, investigational medicine in development for the treatment of narcolepsy; and AXS-14, which is an oral, investigational medicine in development for the treatment of fibromyalgia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
1,575 |
1,575 |
1,575 |
1,575 |
Total Buy Value |
$200,466 |
$200,466 |
$200,466 |
$200,466 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
237,948 |
350,135 |
365,135 |
499,282 |
Total Sell Value |
$28,277,977 |
$40,024,959 |
$41,976,489 |
$52,544,160 |
Total People Sold |
4 |
6 |
7 |
7 |
Total Sell Transactions |
12 |
23 |
25 |
33 |
End Date |
2025-07-06 |
2025-04-04 |
2024-10-04 |
2023-10-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Jacobson Mark L. |
Chief Operating Officer |
|
2025-09-22 |
4 |
AS |
$115.96 |
$1,159,600 |
D/D |
(10,000) |
0 |
|
2% |
|
Jacobson Mark L. |
Chief Operating Officer |
|
2025-09-22 |
4 |
OE |
$2.85 |
$28,500 |
D/D |
10,000 |
10,000 |
|
- |
|
Jacobson Mark L. |
Chief Operating Officer |
|
2025-09-16 |
4 |
AS |
$114.23 |
$5,241,127 |
D/D |
(45,783) |
0 |
|
5% |
|
Jacobson Mark L. |
Chief Operating Officer |
|
2025-09-16 |
4 |
OE |
$4.85 |
$196,500 |
D/D |
40,000 |
40,000 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-09-16 |
4 |
AS |
$114.19 |
$2,251,713 |
D/D |
(19,719) |
7,229 |
|
5% |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-09-16 |
4 |
OE |
$8.02 |
$158,146 |
D/D |
19,719 |
26,948 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-09-15 |
4 |
AS |
$117.37 |
$1,790,362 |
D/D |
(15,254) |
7,229 |
|
3% |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-09-15 |
4 |
OE |
$8.02 |
$122,337 |
D/D |
15,254 |
22,483 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-09-12 |
4 |
AS |
$118.96 |
$3,319,817 |
D/D |
(27,907) |
7,229 |
|
2% |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-09-12 |
4 |
OE |
$8.02 |
$223,814 |
D/D |
27,907 |
35,136 |
|
- |
|
Coleman Mark |
|
|
2025-09-08 |
4 |
B |
$127.20 |
$200,466 |
D/D |
1,575 |
48,212 |
0.01 |
-7% |
|
Saad Mark E |
|
|
2025-09-05 |
4 |
AS |
$125.07 |
$1,141,514 |
D/D |
(9,127) |
10,002 |
|
-4% |
|
Saad Mark E |
|
|
2025-09-05 |
4 |
OE |
$9.00 |
$82,143 |
D/D |
9,127 |
19,129 |
|
- |
|
Jeffs Roger |
|
|
2025-09-02 |
4 |
AS |
$123.68 |
$1,665,228 |
D/D |
(13,464) |
57,510 |
|
-3% |
|
Jeffs Roger |
|
|
2025-08-29 |
4 |
AS |
$121.27 |
$2,425,400 |
D/D |
(20,000) |
70,974 |
|
-1% |
|
Jeffs Roger |
|
|
2025-08-28 |
4 |
AS |
$121.60 |
$2,432,000 |
D/D |
(20,000) |
90,974 |
|
-1% |
|
Jeffs Roger |
|
|
2025-08-27 |
4 |
AS |
$122.30 |
$2,446,000 |
D/D |
(20,000) |
110,974 |
|
-1% |
|
Jeffs Roger |
|
|
2025-08-26 |
4 |
AS |
$120.03 |
$2,400,600 |
D/D |
(20,000) |
130,974 |
|
-1% |
|
Jeffs Roger |
|
|
2025-08-22 |
4 |
AS |
$120.08 |
$2,004,616 |
D/D |
(16,694) |
150,974 |
|
2% |
|
Murdock Hunter R. |
General Counsel |
|
2025-06-23 |
4 |
AS |
$100.12 |
$602,122 |
D/D |
(6,014) |
0 |
|
18% |
|
Murdock Hunter R. |
General Counsel |
|
2025-06-23 |
4 |
OE |
$29.91 |
$179,879 |
D/D |
6,014 |
6,014 |
|
- |
|
Murdock Hunter R. |
General Counsel |
|
2025-06-20 |
4 |
AS |
$102.47 |
$768,525 |
D/D |
(7,500) |
0 |
|
19% |
|
Murdock Hunter R. |
General Counsel |
|
2025-06-20 |
4 |
OE |
$29.91 |
$224,325 |
D/D |
7,500 |
7,500 |
|
- |
|
Murdock Hunter R. |
General Counsel |
|
2025-06-18 |
4 |
AS |
$100.90 |
$756,750 |
D/D |
(7,500) |
0 |
|
17% |
|
Murdock Hunter R. |
General Counsel |
|
2025-06-18 |
4 |
OE |
$29.91 |
$224,325 |
D/D |
7,500 |
7,500 |
|
- |
|
94 Records found
|
|
Page 1 of 4 |
|
|